RET and lung carcinoid tumor: In NETs, including a subset of GEP-NETs, RET mutations or fusions have been implicated in tumorigenesis, including in a case report of successful administration of selpercatinib (a selective RET inhibitor) in a patient with a RET-fusion lung carcinoid tumor [75,76].